

Annals of Oncology 23: 1474–1481, 2012  
doi:10.1093/annonc/mdr448  
Published online 13 October 2011

## Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)

K. Zaman<sup>1\*</sup>, B. Thürlimann<sup>2</sup>, J. Huober<sup>2</sup>, A. Schönenberger<sup>3</sup>, O. Pagani<sup>4</sup>, J. Lüthi<sup>5</sup>, M. Simcock<sup>6</sup>, A. Giobbie-Hurder<sup>7</sup>, G. Berthod<sup>1</sup>, C. Genton<sup>6</sup>, P. Brauchli<sup>6</sup> & S. Aebi<sup>8</sup> on behalf of the Swiss Group for Clinical Cancer Research (SAKK)

<sup>1</sup>Breast Center, CePO, University Hospital, Lausanne; <sup>2</sup>Breast Center, Kantonsspital, St Gallen; <sup>3</sup>Department of Oncology, Kantonsspital, Aarau; <sup>4</sup>Oncology Institute of Southern Switzerland, Ospedale Italiano, Lugano; <sup>5</sup>Department of Oncology, Hospital Thun; <sup>6</sup>SAKK Coordinating Center, Bern, Switzerland; <sup>7</sup>International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, USA; <sup>8</sup>Division of Medical Oncology, University Hospital, Bern, Switzerland

Received 31 May 2011; revised 26 August 2011; accepted 30 August 2011

**Background:** The risk of osteoporosis and fracture influences the selection of adjuvant endocrine therapy. We analyzed bone mineral density (BMD) in Swiss patients of the Breast International Group (BIG) 1-98 trial [treatment arms: A, tamoxifen (T) for 5 years; B, letrozole (L) for 5 years; C, 2 years of T followed by 3 years of L; D, 2 years of L followed by 3 years of T].

**Patients and methods:** Dual-energy X-ray absorptiometry (DXA) results were retrospectively collected. Patients without DXA served as control group. Repeated measures models using covariance structures allowing for different times between DXA were used to estimate changes in BMD. Prospectively defined covariates were considered as fixed effects in the multivariable models.

**Results:** Two hundred and sixty-one of 546 patients had one or more DXA with 577 lumbar and 550 hip measurements. Weight, height, prior hormone replacement therapy, and hysterectomy were positively correlated with BMD; the correlation was negative for letrozole arms (B/C/D versus A), known osteoporosis, time on trial, age, chemotherapy, and smoking. Treatment did not influence the occurrence of osteoporosis ( $T$  score  $< -2.5$  standard deviation).

**Conclusions:** All aromatase inhibitor regimens reduced BMD. The sequential schedules were as detrimental for bone density as L monotherapy.

**Key words:** aromatase inhibitors, BIG 1-98, bone, breast cancer, endocrine therapy, tamoxifen

\*Correspondence to: Dr K. Zaman, Multidisciplinary Center for Oncology, University Hospital CHUV, 46 Rue du Bugnon, 1011 Lausanne, Switzerland.  
Tel: +41-79-556-78-01; Fax: +41-21-314-02-00; E-mail: Khalil.Zaman@chuv.ch

## introduction

Aromatase inhibitors (AIs) are currently part of the standard endocrine therapy in postmenopausal women with early-stage endocrine-sensitive breast cancer [1]. Large randomized trials showed that AIs have a good tolerance and safety profile. However, most of the studies reported a significantly higher rate of bone fractures [2–7], osteoporosis, or osteopenia measured by dual-energy X-ray absorptiometry [7–10] and increase of bone resorption markers compared with tamoxifen [8–10]. Therefore, bone health is a concern when initiating AIs in the adjuvant setting.

In the general population, 30%–50% of postmenopausal women are at risk of osteoporotic fractures [11]. Osteoporosis is a major public health problem as its complications cause significant morbidity [12], alter quality of life [13], and may lead to increased mortality [14]. Estrogen up-regulates the expression of osteoprotegerin, suppresses apoptosis in osteoblasts, and down-regulates the secretion of cytokines promoting osteoclast differentiation [15, 16]. At menopause, estrogens produced by the aromatase activity in the peripheral tissues play a protective role for bone [17]. Since AIs decrease circulating estrogen levels by >90% [18], they reinforce the unfavorable imbalance between bone reabsorption and bone formation observed after menopause [9, 10]. The risk of osteoporosis and fractures therefore worries oncologists as well as patients and influences the decision of whether to use an AI, tamoxifen, or sequences of both. It is therefore important to have reliable information to help in assessing the risk of bone fractures when deciding to select between different types of endocrine therapy.

All the large randomized studies compared up-front treatment with 5 years of tamoxifen versus either 5 years of an AI or a sequential schedule of 2–3 years of tamoxifen followed by 2–3 years of an AI. The Breast International Group (BIG) 1-98 trial, with a four-arm design, is the only study assessing simultaneously the up-front and the sequential use of an AI in 8010 postmenopausal patients [6]: arm A, tamoxifen for 5 years; arm B, letrozole for 5 years; arm C, tamoxifen for 2 years followed by letrozole for 3 years; arm D, letrozole for 2 years followed by tamoxifen for 3 years. The original BIG 1-98 trial did not require bone mineral density (BMD) measurement but did record predefined expected adverse events including bone events every 6 months [2]. After a median follow-up of 60.3 months, a significantly higher rate of fractures was observed in the letrozole monotherapy arm compared with the tamoxifen arm, 9.3% versus 6.5%, respectively [2]. Although fracture is the most clinically relevant end point, BMD is currently the best surrogate in the prevention setting [19] and has been chosen by the World Health Organization as the main diagnostic criterion for osteoporosis.

Despite BMD measurements not being a study requirement, many investigators have determined BMD in their patients at different time points during and after the completion of study treatments particularly after the first published results of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial [20], which reported a higher rate

of bone fractures with anastrozole. The aim of our study was to collect all available BMD measurements of all the BIG 1-98 patients treated in Switzerland irrespective of the bone health status at study entry and to develop a statistical model to describe the evolution of BMD in patients treated in the different arms of BIG 1-98 trial. This was the unique opportunity for a direct comparison between monotherapy and sequential schedules of tamoxifen and an AI in a randomized and double-blinded study.

## patients and methods

### patient selection

The patients included in the BIG 1-98 trial were all postmenopausal women. The eligibility criteria of the patients accrued in BIG 1-98 trial are described elsewhere [21]. Hormone replacement therapy (HRT) had to be stopped at least 4 weeks before initiation of the trial treatment. Concomitant bisphosphonates were allowed and their use was recorded during the trial.

All the patients enrolled in the BIG 1-98 trial by Swiss centers were considered for study entry. Exclusion criteria were as follows: withdrawal of informed consent, known uncontrolled endocrine disease having an impact on bone health (thyroid, parathyroid, Cushing's, pituitary diseases) or any other disease affecting bone health (other than breast cancer and its therapy), adjuvant endocrine therapy for breast cancer other than tamoxifen and letrozole, or metastatic bone disease before the first BMD.

### study design

Data were collected from the International Breast Cancer Study Group (IBCSG) Data Center and the patients' medical files. The IBCSG provided the SAKK with the list of all Swiss patients enrolled in the BIG 1-98 study and the following data: (i) at baseline: unblinded treatment arm, date of inclusion, date of treatment start, age, skeletal-related events (fracture and date), history of osteoporosis, weight, height, prior HRT, oophorectomy, hysterectomy, tobacco history, bisphosphonate use, neoadjuvant or adjuvant chemotherapy, time on treatment, bone disease, other diseases affecting bone health, and uncontrolled endocrine diseases; (ii) during the treatment period: visit dates, bisphosphonate use, patients with breast cancer relapse and date of relapse, study treatment continuation, bone fractures (date, cause, and site), uncontrolled endocrine disease, and patients randomly allocated to the tamoxifen-only arm who switched to letrozole; (iii) follow-up data: visit dates, patients with breast cancer relapse and date of relapse, uncontrolled endocrine disease, and bone fractures (date, cause, and site).

A research associate collected BMD measurements from each center for up to 3 years before inclusion in the BIG 1-98 trial. For patients with none or only one BMD available at the center, the patients' general practitioner and/or gynecologist were contacted in order to know if any additional BMD measurement had been done. The following data were collected for each patient: radiology center, date of assessment, name and characteristics of the used machine, level of measure in the lumbar spine, BMD ( $\text{g}/\text{cm}^2$ ), *T* score, and *Z* score [% and standard deviation (SD)] for lumbar spine and total hip.

The study was carried out in accordance with the Declaration of Helsinki, the Guidelines of Good Clinical Practice issued by the International Conference on Harmonization, and the Swiss regulatory authority's requirements. The study was approved by the local ethics committees and the Swiss 'Experts' commission of professional secrecy for medical research'.

### statistical considerations

The data were first split into two groups: one group containing patients with at least one recorded BMD measurement and the second group containing patients with no BMD measurements. The second group was used as a bias assessment group in order to detect any between-group imbalance in baseline characteristics. To reduce bias, such imbalanced characteristics have been included in the final statistical model.

All baseline variables included in the analysis were summarized descriptively: frequency (percentage) by category for categorical variables and median (quartile range) for continuous variables. This was done individually for both the study group and the bias assessment group and the two groups compared using a Chi-squared test for the categorical variables and the Mann–Whitney–Wilcoxon test for continuous variables.

Differences between treatment arms were not considered during the descriptive analysis as patients had been randomly assigned to the treatment arms, stratified according to the participating center and neo/adjuvant chemotherapy use.

The statistical model used to describe BMD changes was a repeated measures model that allowed for multiple BMD measurements from individual patients. To use as much of the available information as possible, the first BMD measurement was included in the response variable along with the BMD measurements collected after randomization. The first-order autoregressive covariance structure was used in the model to allow for the differences in time between different BMD measurements. All covariates considered to be of importance in the prediction of BMD were first considered in a univariate model as fixed effects before being considered simultaneously in a multivariate model. When modeling BMD change, the time to the BMD measurement was also considered and recorded in months from the time of BIG 1-98 trial registration. Machine type and center were modeled as random variables in the mixed repeated measures model to allow for natural variation between center and machine type used in the BMD measurement recordings. Other variables remaining in the model were considered to be the risk factors and their influence on the BMD shown. A smoothed line was plotted through the actual data points per treatment arm based on the actual BMD measurement against time.

Due to the significant number of patients in arm A that crossed over to letrozole [6], BMD measurements were modeled using the intention-to-treat (ITT) principle as well as the per-protocol (PP) principle. This means that the patients in treatment arm A were analyzed using the trial therapy as intended and not allowing for the unplanned crossover under the ITT principle, while the PP principle means their observations were ignored after the time of crossover.

### role of the funding source

Novartis had no role in the study design, data analyses, or results interpretation.

## results

A total of 546 patients (arm A, 133; B, 137; C, 141; and D, 135) from 11 centers were included in this study (Figure 1). Overall, 261 of them (48%) had at least one BMD measurement (Table 1). One patient was excluded due to unrealistic BMD values. Patients' baseline characteristics are described in Table 2. No major differences were observed between patients with BMD measurements and those without. Less than 1% of the patients were using bisphosphonates at baseline. Six patients in arm A, three in




Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram.

arm B, and one in arm D received bisphosphonates during study treatment. The median baseline *T* scores were  $-1.15$  SD and  $-0.60$  SD in the lumbar spine and hip, respectively. The patients with osteoporosis represented 6.2% of the studied population. The numbers of patients presenting lumbar osteopenia were 27, 23, 22, and 29 in arms A, B, C, and D, respectively. Those with hip osteopenia were 21, 26, 21, and 24, respectively.

A total of 577 lumbar BMD measurements were collected: arm A, 155; arm B, 150; arm C, 132; and arm D, 140. The proportion of patients with more than one BMD was 73% ( $n = 179$ ). The number of the total hip measurements recorded was 550: arm A, 150; arm B, 142; arm C, 132; and arm D, 126. The median number of measurements per patient was two for both locations. Sixty percent ( $n = 349$ ) of the BMD were measured during the endocrine treatment period and 40% ( $n = 228$ ) during the following years (Table 3).

In the univariate and multivariate analyses, treatment in any of the letrozole-containing arms and history of osteoporosis were significant predictors of lumbar spine BMD loss. Higher weight and height, previous hysterectomy, and HRT use were associated with less BMD loss. The multivariate analyses also revealed time since randomization as a significant negative factor (Table 4). For the total hip BMD, the univariate analyses showed treatment in arm B, age, history of osteoporosis, smoking (current versus never), and bisphosphonate use as predictors of BMD loss, whereas weight and height were predictors of BMD preservation. In the multivariate analyses, the association of all these parameters was still significant except for bisphosphonate use and height. In addition, not only treatment arm B but all the letrozole-containing arms were significant predictors of increased bone loss compared with the tamoxifen-only treated patients (Table 5). When analyzing the treatment arms as predictors of osteoporosis, defined as a *T* score  $\leq -2.5$  SD, none of them showed a statistically significant impact. The data based on the ITT principle were concordant with those based on the PP principle (not presented).

## discussion

The results of our analysis show that in all three letrozole-containing arms, the loss of BMD is significantly higher than

**Table 1.** Study patients' distribution

Type of measurement	Number of patients per treatment arm				Total number of patients
	A	B	C	D	
Lumbar BMD	66	63	55	62	246
Lumbar <i>T</i> score	66	63	59	63	251
Total hip BMD	65	59	56	56	236
Total hip <i>T</i> score	61	55	51	53	220

BMD, bone mineral density.

**Table 2.** Baseline characteristics of the eligible population

Factors	Patients with		<i>P</i> value
	No BMD measured ( <i>n</i> = 285)	One or more BMD measured ( <i>n</i> = 261)	
Continuous factors	Median (quartile range)		
Weight (kg)	67 (44 to 117)	65 (43 to 114)	0.006
Height (cm)	163 (146 to 180)	162 (145 to 182)	0.180
Age at randomization (years)	63 (47 to 86)	61 (41 to 81)	0.017
Lumbar BMD <sup>a</sup> , g/cm <sup>2</sup>		0.962 (0.687 to 1.474)	
Lumbar <i>T</i> score SD BMD <sup>a</sup>		-1.15 (-3.30 to 3.60)	
Total hip BMD <sup>a</sup> , g/cm <sup>2</sup>		0.891 (0.613 to 1.127)	
Total hip <i>T</i> score SD BMD <sup>a</sup>		-0.60 (-3.00 to 1.20)	
Categorical factors	<i>n</i> (%)		
Race, white	285 (99.65)	260 (100.00)	1.000
Osteoporosis	7 (2.45)	16 (6.15)	0.031
Smoking			
Previously	35 (12.28)	39 (15.06)	0.254
Ongoing	57 (20.00)	39 (15.06)	
Never	193 (67.72)	181 (69.88)	
Bone fracture (last 10 years)	17 (5.94)	18 (6.92)	0.641
Hysterectomy	98 (34.27)	71 (27.31)	0.079
HRT within the last 5 years	125 (43.70)	129 (49.61)	0.519
Using bisphosphonate	1 (0.35)	2 (0.77)	0.795
Neo/adjuvant chemotherapy	77 (26.92)	98 (37.69)	0.007

<sup>a</sup>Using nearest recorded measurement to randomization date (within  $\pm 1$  to 3 years).

BMD, bone mineral density; HRT, hormone replacement therapy; SD, standard deviation.

**Table 3.** BMD measurements since randomization

Years since randomization	Lumbar BMD ( <i>n</i> = 577)				Total hip BMD ( <i>n</i> = 550)			
	Treatment arms							
	A	B	C	D	A	B	C	D
0-1	9	15	5	10	9	14	5	10
1-2	4	9	12	6	4	9	12	5
2-3	19	11	19	10	19	10	19	7
3-4	19	24	15	25	19	21	15	22
4-5	40	37	32	29	40	37	33	26
5-6	38	35	28	31	36	33	29	30
6-7	22	15	16	21	20	14	15	19
>7	6	4	5	8	5	4	4	7

BMD, bone mineral density.

in the tamoxifen-only arm. Contrary to expectations, the sequential administration of tamoxifen followed by letrozole has no long-term protective effect on BMD despite the

shorter exposure to AI and the previous administration of tamoxifen (Figure 2). Patients treated with tamoxifen increased their BMD but observed a deep fall when switching

**Table 4.** Univariate and multivariate analysis of lumbar spine BMD predictors (ITT)

Factor	Estimate (standard error)				
	Category	Univariate	P value	Multivariate	P value
Age (years)		-0.002 (0.001)	0.0892	-	
Weight (kg)		0.002 (0.001)	<0.0001	0.002 (0.001)	<0.0001
Height (cm)		0.005 (0.001)	<0.001	0.004 (0.001)	0.0005
Hysterectomy	Yes versus no	0.052 (0.015)	0.0005	0.057 (0.014)	<0.0001
Osteoporosis	Yes versus no	-0.113 (0.026)	<0.0001	-0.138 (0.025)	<0.0001
Smoking status	Current versus never	0.030 (0.019)	0.1204	0.028 (0.019)	0.1429
	Did versus never	0.072 (0.017)	<0.0001	0.071 (0.016)	<0.0001
HRT	Yes versus no	0.029 (0.013)	0.0275	0.031 (0.014)	0.0239
Bisphosphonate use	Continuing versus never	-0.138 (0.088)	0.1179	-	
Treatment arm	B versus A	-0.051 (0.018)	0.0053	-0.042 (0.017)	0.0132
	C versus A	-0.078 (0.019)	<0.001	-0.073 (0.018)	<0.0001
	D versus A	-0.058 (0.019)	0.0019	-0.047 (0.017)	0.0071
Previous neo/adjuvant chemotherapy	Yes versus no	0.014 (0.014)	0.2863	-	
Time since randomization		-0.004 (0.004)	0.1832	-0.010 (0.004)	0.0051

BMD, bone mineral density; HRT, hormone replacement therapy; ITT, intention-to-treat.

**Table 5.** Univariate and multivariate analysis of total hip BMD predictors (ITT)

Factor	Estimate (standard error)				
	Category	Univariate	P value	Multivariate	P value
Age (years)		-0.004 (0.001)	<0.0001	-0.004 (0.001)	<0.0001
Weight (kg)		0.004 (0.001)	<0.0001	0.004 (0.004)	<0.0001
Height (cm)		0.003 (0.001)	0.0003	-	
Hysterectomy	Yes versus no	0.021 (0.012)	0.0815	-	
Osteoporosis	Yes versus no	-0.100 (0.021)	<0.0001	-0.084 (0.019)	<0.0001
Smoking status	Current versus never	-0.032 (0.016)	0.0481	-0.047 (0.015)	0.0013
	Did versus never	0.018 (0.014)	0.1765	0.013 (0.012)	0.2768
HRT	Yes versus no	0.010 (0.011)	0.3518	0.022 (0.009)	0.0174
Bisphosphonate use	Continuing versus never	-0.156 (0.070)	0.0250	-	
Treatment arm	B versus A	-0.035 (0.014)	0.0159	-0.039 (0.012)	0.0015
	C versus A	-0.022 (0.015)	0.1281	-0.041 (0.013)	0.0015
	D versus A	-0.017 (0.015)	0.2601	-0.032 (0.013)	0.0119
Previous neo/adjuvant chemotherapy	Yes versus no	-0.012 (0.011)	0.2691	-	
Time since randomization		-0.001 (0.003)	0.8980	-	


BMD, bone mineral density; HRT, hormone replacement therapy; ITT, intention-to-treat.

to letrozole after 2 years, particularly in the lumbar spine. Conversely, starting with letrozole induced a loss, but the switch to tamoxifen after 2 years improved BMD considerably. This hypothesis is also supported by the bone fracture rate reported in the BIG 1-98 main trial [6]. The incidence of fractures among women assigned to tamoxifen or letrozole followed by tamoxifen was lower than in women treated with tamoxifen followed by letrozole or letrozole alone (7.3%, 7.5%, 9.4%, and 9.8%, respectively).

Tamoxifen is known to increase or to stabilize bone density and to decrease fracture rate in postmenopausal patients [22]. The reason why there is no persisting benefit after 2 years of tamoxifen during the following AI treatment in terms of BMD is not known so far. However, a rebound phenomenon is suspected. The interruption of tamoxifen combined with the

rapid fall in estrogen levels induced by the AI may promote an accelerated loss of BMD following the switch [7, 23, 24]. McCaig et al. [25] reported that stopping tamoxifen and starting AIs results in a significantly greater increase in bone turnover compared with commencing AIs in tamoxifen-naive patients. The measurement of bone turnover biomarkers also showed that the effect of AIs occurs relatively rapidly after initiation of the treatment [9, 24, 26–29].

Bone fracture rates in the AI arms reported in the large randomized trials were higher with the up-front use of AIs than with the sequential administration of tamoxifen followed by AI: ATAC trial (68 months), 11% versus 7.7%; BIG 1-98 trial monotherapy arms (51 months), 8.6% versus 5.8%; Austrian Breast and Colorectal Cancer Study Group (ABCSSG)/Arimidex-Nolvadex (ARNO) trial (28 months),



**Figure 2.** Bone mineral density evolution over time: (A) lumbar; (B) total hip.

2% versus 1%; Inter-Group Exemestane (IES) trial, 7% versus 4.9%. However, the odds ratio in the control arm appears to be similar between the up-front AI (ATAC and BIG 1-98 trials) and the switch schedules (IES and ABCSG/ARNO trials). The fracture rates in the ATAC, BIG 1-98 monotherapy arms and IES trials were 21.6, 22.0, and 20.1 per 1000 patients per year, respectively [30]. This supports the absence of a significant persistent bone protective effect of 2–3 years of tamoxifen when followed by AI. These observations are, however, not in accordance with the findings of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial investigating 5 years of exemestane alone versus 2–3 years of tamoxifen followed by exemestane [31]. They reported a lower rate of fracture and osteoporosis in the sequential arm (3% versus 5% and 6% versus 10%, respectively) [32]. The results of the prospective bone substudy of BIG 1-98 trial will soon bring additional information.

In addition to the endocrine therapy, our model also highlights other factors that may have a significant impact on BMD changes during treatment such as weight, height, age,

time since randomization, history of osteoporosis, previous hysterectomy, HRT, and smoking. All these parameters are known to influence bone density and fracture risk in the general population. The significance of hysterectomy as a protective factor is unclear, but it could be a surrogate marker for prior estrogen exposure and its associated endometrial pathologies [33]. Patients with higher estrogen exposure might have a more resistant bone structure and also an increased risk of uterine adverse events leading to hysterectomy.

In our model, the allocation of the treatment arm did not significantly influence the occurrence of osteoporosis, defined as a  $T$  score  $< -2.5$  SD. This is in line with the results of the ATAC bone substudy presented by Eastell et al. [8]. Patients with initially normal BMD had a low risk of developing osteoporosis secondary to the endocrine therapy.

Some limitations have to be considered in our study. First, BMD is not a perfect surrogate marker for fracture risk.

Indeed, most fractures occur even if the threshold of osteoporosis is not reached [34]. BMD reflects mainly bone cortical mass and is poorly representative of the microarchitecture [35]. Secondly, this is not a prospectively randomized trial but a statistical modeling study based on unplanned BMD measurements; therefore, the results have to be considered with caution. The retrospective collection of the measurements did not allow central quality control of the BMDs even if machine types and centers were modeled as random variables. Despite data on many factors known to influence bone health being available and considered in our model (age, weight, height, smoking, personal history of fracture, osteoporosis, previous HRT, bisphosphonate use, and previous neo/adjuvant chemotherapy), others (calcium and vitamin D use, medications known to influence bone turnover, nutrition, physical activity, parathyroid hormone level, time since menopause, and family history of hip fracture) were not available. Nevertheless, the comparison between the different treatment arms, the initial randomization and the multivariate analyses might have attenuated the risk of imbalance. No major difference was observed between the study population and the noninvestigated group of Swiss patients treated in BIG 1-98 trial (bias assessment group). The characteristics of our study population were also similar to those of the BIG 1-98 main study in terms of age, body mass index, history of bisphosphonate use, history of bone fractures, smoking, and HRT use before randomization [2]. In addition, only 12% of the data cover the first 2 years of treatment and 22% 3 years. Our model has therefore more influence for the last years of treatment. The prior inclusion of all patients in this analysis is a strength of the study minimizing the selection bias seen with most bone substudies of AI trials requesting predefined bone entry criteria. Nevertheless, despite the described measures of caution, the influence of other unknown confounders is not excluded.

As the prognosis of early breast cancer patients improves, the long-term safety of adjuvant treatment is increasingly important. Based on our results and other concordant data described above, the decision on whether to administer up-front AI versus a sequential schedule of tamoxifen followed

by AI should not be based on bone health considerations but rather on other factors, i.e. clinical tolerance, cost, comorbidities, risk of relapse, and patient's preference. Several studies showed that bisphosphonates [36] or denosumab [37] could successfully stabilize bone density during endocrine therapy with AIs at least in nonosteoporotic patients. The risk of osteoporosis and bone fracture can be managed by following the published experts' recommendations [38, 39]. Our observation refers to postmenopausal women. The impact of endocrine treatment on bone health in premenopausal women is unknown; for premenopausal patients, investigation of BMD changes and bone remodeling is ongoing in the Tamoxifen and Exemestane (TEXT) trial.

In conclusion, our study shows that all AI regimens, up-front or sequential, affect BMD to different degrees. Contrary to expectation, the switch strategy starting with tamoxifen before AI administration does not seem to confer a protective effect on bone health. The converse regimen, AI followed by tamoxifen, may offer a better benefit in terms of efficacy and bone safety [6]. The results of this unplanned and retrospective substudy of the BIG 1-98 trial need future confirmation.

## acknowledgements

We would like to thank Rahel Kindler who carried out much of the BMD measurement collection for this study.

## funding

State Secretariat for Education and Research (SER); Novartis Switzerland.

## disclosure

The following authors have declared conflict of interest—BT: stock of Novartis, travel grant for educational activities from Novartis, and honorarium from Astrazeneca for educational activities; JH: advisory relationship with Novartis and Astrazeneca and honorarium from Novartis and Astrazeneca. The following authors have declared no conflict of interest: KZ, AS, OP, JL, MS, AG-H, GB, CG, PB, and SA.

## references

- Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. *Ann Oncol* 2009; 20: 1319–1329.
- Rabaglio M, Sun Z, Price KN et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. *Ann Oncol* 2009; 20: 1489–1498.
- Forbes JF, Cuzick J, Budzar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. *Lancet Oncol* 2008; 9: 45–53.
- Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. *Lancet* 2005; 366: 455–462.
- Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. *Lancet* 2007; 369: 559–570.
- Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. *N Engl J Med* 2009; 361: 766–776.
- Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. *Lancet Oncol* 2007; 8: 119–127.
- Eastell R, Adams JE, Coleman RE et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. *J Clin Oncol* 2008; 26: 1051–1057.
- Lonning PE, Geisler J, Krag LE et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. *J Clin Oncol* 2005; 23: 5126–5137.
- Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. *J Clin Oncol* 2006; 24: 3629–3635.
- Melton LJ 3rd, Chrischilles EA, Cooper C et al. Perspective. How many women have osteoporosis? *J Bone Miner Res* 1992; 7: 1005–1010.
- Leidig-Bruckner G, Minne HW, Schlaich C et al. Clinical grading of spinal osteoporosis: quality of life components and spinal deformity in women with chronic low back pain and women with vertebral osteoporosis. *J Bone Miner Res* 1997; 12: 663–675.
- Adachi JD, Ioannidis G, Pickard L et al. The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). *Osteoporos Int* 2003; 14: 895–904.
- Center JR, Nguyen TV, Schneider D et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. *Lancet* 1999; 353: 878–882.
- Saika M, Inoue D, Kido S, Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. *Endocrinology* 2001; 142: 2205–2212.
- Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. *Proc Natl Acad Sci U S A* 2000; 97: 7829–7834.
- Cummings SR, Browner WS, Bauer D et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. *N Engl J Med* 1998; 339: 733–738.
- Geisler J, Haynes B, Anker G et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. *J Clin Oncol* 2002; 20: 751–757.
- Johnell O, Kanis JA, Oden A et al. Predictive value of BMD for hip and other fractures. *J Bone Miner Res* 2005; 20: 1185–1194.
- Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet* 2002; 359: 2131–2139.
- Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. *N Engl J Med* 2005; 353: 2747–2757.
- Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. *N Engl J Med* 1992; 326: 852–856.
- Cohen A, Fleischer JB, Johnson MK et al. Prevention of bone loss after withdrawal of tamoxifen. *Endocr Pract* 2008; 14: 162–167.

24. Hadji P, Ziller M, Kieback DG et al. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. *Breast* 2009; 18: 159–164.
  25. McCaig FM, Renshaw L, Williams L et al. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. *Breast Cancer Res Treat* 2010; 119: 643–651.
  26. McCloskey EV, Hannon RA, Lakner G et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. *Eur J Cancer* 2007; 43: 2523–2531.
  27. Gonnelli S, Cadirni A, Caffarelli C et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. *Bone* 2006.
  28. Eastell R, Hannon RA, Cuzick J et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). *J Bone Miner Res* 2006; 21: 1215–1223.
  29. Van Poznak C, Hannon RA, Mackey JR et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. *J Clin Oncol* 2010; 28: 967–975.
  30. Goss P, O'Shaughnessy J, Mamounas E. Counteracting bone loss associated with breast cancer therapies. *Medsc Hematol Oncol* 2008.
  31. Rea D, HA, Seynaeve C Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. In San Antonio Breast Cancer Symposium, December 10, 2009. Abstract 11.
  32. van de Velde CJ, Rea D, Seynaeve C et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. *Lancet* 2011; 377: 321–331.
  33. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *N Engl J Med* 2003; 349: 1793–1802.
  34. Siris ES, Chen YT, Abbott TA et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. *Arch Intern Med* 2004; 164: 1108–1112.
  35. Pothuau L, Barthe N, Krieg MA et al. Evaluation of the potential use of trabecular bone score to complement bone mineral density in the diagnosis of osteoporosis: a preliminary spine BMD-matched, case-control study. *J Clin Densitom* 2009; 12: 170–176.
  36. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. *Breast* 2006; 15 (Suppl 1): S30–S40.
  37. Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. *J Clin Oncol* 2008; 26: 4875–4882.
  38. Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. *Ann Oncol* 2008; 19: 1407–1416.
  39. Reid DM, Doughty J, Eastell R et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. *Cancer Treat Rev* 2008; 34 (Suppl 1): S3–S18.
-